U.S. stock night trading volatility: Mannkind fell 7.87% in night trading, pressured by poor earnings report and market concerns

U.S. Stock Night Market Movements MannKind Corporation fell 7.87% in the night market. Based on recent news, On May 6, MannKind announced its first-quarter financial report, showing a net income of -$16.619 million, earnings per share of -$0.05, and operating income of -$1.667 million. These poor financial results led to a decline in stock price. On May 6, analysts maintained a buy rating on MannKind with a target price of $8. However, market concerns increased regarding its reliance on United Therapeutics, as a significant portion of its revenue comes from this company. On May 6, MannKind announced progress in its long-term R&D projects, but the market still has doubts about its future profitability, putting pressure on the stock price. The biotechnology sector has shown volatility recently, and investors should be cautious. Stocks with High Trading Volume in the Industry BeiGene fell 0.37% in the night market. Based on recent key news: On May 6, BeiGene reported a 34% increase in first-quarter revenue, reaching $1.5 billion, primarily driven by a 38% increase in BRUKINSA and strong global demand. The full-year revenue guidance was raised by $100 million, with good progress in hematology and solid tumor pipelines, and gross margins continuing to expand. These positive financial results boosted market confidence, but the stock price still experienced volatility. On May 6, BeiGene expected gross margins to remain at the high end of 80%. Despite the favorable gross margin outlook, market concerns about future profitability may lead to stock price fluctuations. On May 7, analysts maintained a buy rating on BeiGene and raised the target price to $395. The analysts' positive evaluations and target price increase had a positive impact on the stock price, but market reactions remained complex. The market maintains a cautiously optimistic attitude towards the biopharmaceutical industry's prospects, with capital flows indicating active trading. Moderna rose 1.39% in the night market. Based on recent key news: On May 5, UBS raised Moderna's target price from $36 to $45 and maintained a "Neutral" rating. UBS pointed out that the upcoming product line updates in 2026 could improve investor sentiment, especially as late-stage data on personalized cancer vaccines is seen as a significant catalyst for 2026, driving the stock price up by 4.6%. On May 6, Moderna's flu vaccine was approved in the EU. The approval of this vaccine helps reduce the risks associated with the flu and COVID-19 combination vaccines, further boosting market confidence. On May 7, regulators accepted Moderna's revised application, committing to additional research after the vaccine's approval. This progress alleviated market concerns about vaccine approvals, supporting the stock price increase. The vaccine industry is focused on product line updates and approval progress ADMA Biologics fell 20.44% in after-hours trading. Based on recent key news: On May 6, ADMA Biologics announced its first-quarter financial report showing an adjusted net income of $40.7 million, below the market expectation of $48.4 million, leading to a significant drop in stock price. Source: Reuters On May 6, ADMA Biologics' Q1 revenue was $114.5 million, falling short of the market expectation of $141.8 million, further exacerbating market concerns about its profitability. Source: Reuters On May 4, the FDA approved ADMA Biologics to expand the label usage of ASCENIV, although this positive news failed to offset the negative impact of the poor financial report. Source: Public Technologies The biopharmaceutical industry is facing competitive pressure, and market volatility is increasing